Remove Genetic Analysis Remove Production Remove Reagent
article thumbnail

Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel

The Pharma Data

.” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. “Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers. .”

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

Medical device manufacturers are leveraging these technologies to enhance their products, supporting healthcare providers and improving patient outcomes. This reduces human error and contamination risks, ensuring higher-quality production outcomes. The global next-generation biomanufacturing market is projected to grow at a CAGR of 14.85